Despite recent advances in pulmonary arterial hypertension (PAH) treatment, this condition is still characterized by an extremely poor prognosis. In this review, we discuss the use of newly-approved drugs for PAH treatment with already known mechanisms of action (macitentan), innovative targets (riociguat and selexipag), and novel therapeutic approaches with initial up-front combination therapy. Secondly, we describe new potential signalling pathways and investigational drugs with promising role in the treatment of PAH.

New drugs, therapeutic strategies, and future direction for the treatment of Pulmonary Arterial Hypertension

Mercurio, Valentina
;
BIANCO, ANNA;CAMPI, GIACOMO;MANCINI, ANGELA;Parrella, Paolo;Petretta, Mario;Bonaduce, Domenico
2019

Abstract

Despite recent advances in pulmonary arterial hypertension (PAH) treatment, this condition is still characterized by an extremely poor prognosis. In this review, we discuss the use of newly-approved drugs for PAH treatment with already known mechanisms of action (macitentan), innovative targets (riociguat and selexipag), and novel therapeutic approaches with initial up-front combination therapy. Secondly, we describe new potential signalling pathways and investigational drugs with promising role in the treatment of PAH.
File in questo prodotto:
File Dimensione Formato  
Mercurio V Curr Med Chem 2019.pdf

solo utenti autorizzati

Licenza: Accesso privato/ristretto
Dimensione 843.09 kB
Formato Adobe PDF
843.09 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/698720
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 16
social impact